Insurers defend remote monitoring they themselves tried to restrict

Major US health insurers are pushing back against a Medicare proposal that would change how doctors bill for monitoring patients with devices such as connected blood pressure cuffs, scales and glucose meters. Remote patient monitoring (RPM) helps patients manage conditions including hypertension, diabetes and heart failure.

UnitedHealth Group, CVS Health and Kaiser Permanente have written to the Centers for Medicare and Medicaid Services to oppose the plan. It would require the practice that submits the claim to deliver remote monitoring care through its own direct employees, which in practice would ban subcontractors. All three groups run both an insurance business and a care organization.

An internal contradiction

The objection from UnitedHealth Group stands out. Its insurance subsidiary, UnitedHealthcare, recently tried to stop paying for most remote patient monitoring, citing "insufficient evidence of effectiveness." The same company now appears in two roles: as a payer questioning the value of the service, and as a care provider defending the billing model.

For patients the stakes are practical, not political. Remote monitoring makes sense where it catches a decline without a visit. Take a heart failure patient whose change in body weight signals fluid retention. If the service is billed but delivered by third parties, a question of responsibility arises: who reacts to the alert, who documents it and who answers for the outcome. The agency's proposal shifts that role to the practice that submits the bill.

The mechanism at issue is not whether the devices exist, but who may bill for handling them. A patient can still measure blood pressure or weight at home. The dispute is whether an outside company may receive and interpret the data, or only the practice's own staff. In a model where care is increasingly bought as a service, that difference decides who keeps in contact with the patient and who carries the risk when an alert is missed.

At the same time the agency is promoting the ACCESS program, in which it pays for chronic disease management and bills for the outcome. The direction is consistent: Medicare is trying to shift the emphasis from the number of services performed to their effect. The problem is that the tools used to achieve those effects are subject to conflicting regulatory signals at the same time.

For patients the practical effect is limited: the device still works and the data still reach the record. What changes is the number of entities that may analyze and bill for them, and that translates into how quickly a patient hears back from someone who knows their history.